Biogen pushes in a fresh stack of chips and starts prepping a global R&D game plan after watching the cards turn on early thrombolytic data

John Carroll

Editor & Founder

After patiently steering through a decade-long journey for its early-stage clinical work, a small Tokyo biotech has clinched a deal to out-license its lead thrombolytic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen pushes in a fresh stack of chips and starts prepping a global R&D game plan after watching the cards turn on early thrombolytic data

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Kallyope quietly reports Phase 2 obesity data, begins mid-stage migraine trial

Startup working on oral antibodies shares early ulcerative colitis data

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

How AI can address ongoing challenges in the life sciences industry

Bio­gen push­es in a fresh stack of chips and starts prep­ping a glob­al R&D game plan af­ter watch­ing the cards turn on ear­ly throm­bolyt­ic da­ta

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Biogen pushes in a fresh stack of chips and starts prepping a global R&D game plan after watching the cards turn on early thrombolytic data